# 2025-11781: FDA Assigns a Newborn Screening Test to Class II

2025-11781, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Lysosomal Storage Disorder Newborn Screening Test System, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-06-26; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11781
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11781
- Title: Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Lysosomal Storage Disorder Newborn Screening Test System
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27229
- Published: 2025-06-26
- Effective: 2025-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Assigns a Newborn Screening Test to Class II

## Summary

The FDA is officially putting the lysosomal storage disorder newborn screening test system into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and effective while speeding up access to new, helpful devices for babies. The new rules took effect on June 26, 2025, making it simpler and less costly for companies to bring these lifesaving tests to hospitals.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is classifying the lysosomal storage disorder newborn screening test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the lysosomal storage disorder newborn screening test system's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Newborn Screening Tests Reclassified to Class II: benefit, high. The FDA officially classified the lysosomal storage disorder newborn screening test system as Class II (special controls) effective June 26, 2025, with the classification applicable on February 3, 2017. The device is subject to premarket notification under section 510(k), and FDA states this will r…
- Required Clinical Studies and Lab Performance Rules: benefit, medium. Manufacturers must perform clinical validation using well-characterized clinical specimens from the intended newborn population and testing by representative operators, and must demonstrate things like reference intervals, limit of detection/quantitation, carryover/drift, and imprecision. The rule…
- Labeling Must Disclose Limits and Error Rates: benefit, medium. Labeling for these tests must include a warning that the test is not intended to diagnose lysosomal storage disorders and must state that results should be used with other clinical findings and confirmed by alternative methods. Labels must also include detailed device performance data from the clin…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11781 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11781/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classification-of-the-lysosomal)
- [2025-11781 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11781.pdf)

## Related
- [Previous: 2025-11780, Protection of Stratospheric Ozone; CFR Correction](https://policyrisk.com/federal-register/2025-11780)
- [Next: 2025-11791, Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Atten…](https://policyrisk.com/federal-register/2025-11791)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11781 (as of 2026-11-05).
